Edwards Lifesciences stock gains as Q2 growth and bullish options activity support outlook

Edwards Lifesciences stock (ISIN US28176E1082) is trading around USD 90.86 as of September 1, 2026, close to its recent highs after investors digested strong second-quarter figures and fresh signs of bullish options positioning, according to data summarized by Barchart and MarketBeat.

Q2 2026 figures show double-digit growth

According to a detailed overview of Edwards Lifesciences' second-quarter results reported by Barchart, Edwards Lifesciences generated Q2 revenue growth of 13.6 percent year over year, underscoring robust demand for its heart-valve therapies in the period ended June 30, 2026.

The same Barchart summary highlights that adjusted earnings per share in Q2 reached USD 0.78, up 16.4 percent from adjusted EPS of USD 0.67 in the prior-year quarter, demonstrating significant operating leverage as revenue expanded.

In conjunction with the Q2 release on July 23, 2026, Edwards Lifesciences raised its full-year 2026 revenue guidance and reaffirmed its 2026 adjusted EPS guidance in a range of USD 2.95 to USD 3.05, which represents an increase of 17.2 percent compared with adjusted EPS of USD 2.56 reported for 2025, according to the same Barchart analysis.

Analyst targets and options activity support the stock

Beyond the reported figures, Edwards Lifesciences stock is also benefiting from a supportive analyst and derivatives backdrop. A consensus overview compiled by MarketBeat on September 1, 2026 shows that Edwards Lifesciences carries an average rating of moderate buy based on recent broker research.

The same MarketBeat consensus indicates an average 12-month price target of USD 100.27, implying upside from a referenced share price of USD 90.86 and signaling that analysts see further room for appreciation if the company delivers on its guidance.

On the derivatives side, Barchart reports unusually high volume in put options tied to Edwards Lifesciences, with positioning interpreted as constructive for the stock at a spot price of USD 90.78 during midday trading on August 31, 2026. At that point, Edwards Lifesciences shares had rebounded noticeably from a recent low of USD 82.63, recorded on July 24, 2026, shortly after the Q2 earnings release, illustrating a recovery of about 9.9 percent from that trough level.

Valuation metrics and peer context

The Barchart analysis calculates that, based on an assumed next-12-month earnings per share of USD 3.19 derived from analyst projections for 2027, Edwards Lifesciences stock is currently trading at approximately 28.5 times forward earnings at a price of USD 90.78, a multiple that reflects investors' willingness to pay for structural growth in transcatheter heart therapies.

Using this same earnings estimate, a target valuation multiple of 33.35 times implies a theoretical value of USD 106.39 per share, some 17 percent above the USD 90.78 price referenced in the analysis, underlining that a premium valuation remains contingent on the company meeting its raised guidance and maintaining double-digit revenue and EPS growth.

Edwards Lifesciences also sits within a broader medtech universe that includes DACH-listed peers such as Siemens Healthineers, which gives European investors a familiar benchmark when assessing margins, growth and valuation in advanced cardiovascular technologies, even though Edwards Lifesciences itself is listed on the New York Stock Exchange in the United States.

Heart-valve portfolio underpins growth

Edwards Lifesciences is best known for its transcatheter aortic valve replacement systems and related structural heart therapies, which continue to drive revenue in the structural heart segment and underpin the Q2 2026 growth profile cited by Barchart.

For investors, the key question over the next few quarters will be how quickly new indications and next-generation devices broaden the addressable market and whether these innovations sustain revenue growth at or above the 13.6 percent year-over-year pace recorded in Q2 2026.

Stock near recent highs for long-term investors

Shares of Edwards Lifesciences recently opened at USD 90.86 on September 1, 2026, with MarketBeat and related market-data commentary citing this level as the current reference price for the stock.

At this price, Edwards Lifesciences is trading close to a reported 52-week high of USD 96.29 referenced in market coverage by Investing.com, leaving a buffer of only a few dollars between the current level and the upper end of the recent trading range and underscoring that expectations for continued earnings growth are already partly reflected in the valuation.